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Abstract
Background: The prevalence of gestational diabetes mellitus (GDM) is increasing globally which is associated with
various side effects for mothers and fetus. It seems that metabolomic profiling of the amino acids may be useful in early
diagnosis of metabolic diseases. This study aimed to explore the association of the amino acids profiles with GDM.
Methods: Eighty three pregnant women with gestational age ≥25 weeks were randomly selected among pregnant
women referred to prenatal care clinic in Arash hospital of Tehran, Iran. Women divided into three groups including 1)
25 pregnant women with normal glucose tolerance test, 2) 27 pregnant women with diabetes type 2 (T2D) (n: 27) and
3) 31 women with GDM (n: 31). Plasma levels of amino acids were measured by high performance liquid
chromatography and were compared in three groups. Statistical analysis was performed using SPSS 16.
Results: Compared with normal mothers, GDM mothers showed higher plasma concentrations of Arginine (P = 0.01),
Glycine (P = 0.01) and Methionine (P = 0.04), whereas the pregnant women with T2D had higher plasma levels of
Asparagine (P = 0.01), Tyrosine (P < 0.01), Valine (P < 0.01), Phenylalanine (P < 0.01), Glutamine (P < 0.01) and Isolucine
(P < 0.01). The results of regression analyses confirmed the significantly elevated in plasma concentration of Asparagine
(OR:3.64, CI 1.22–10.47), Threonine (OR:3.38, CI 1.39–8.25), Aspartic acid (OR:3.92, CI 1.19–12.91), Phenylalanine (OR:2.66,
CI 1.01–6.94), Glutamine (OR:2.53, CI 1.02–6.26) and Arginine (OR:1.96, CI 1.02–3.76) after adjustment for gestational age
and BMI in GDM mothers compared to normal ones.
Conclusions: Amino acids levels are associated with risk of GDM and diabetes mellitus. However further prospective
studies are needed to clarify the role of different metabolites involved in mechanism of GDM.
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Background
Gestational diabetes mellitus (GDM) is a condition in
which pregnant women without formerly diagnosed dia-
betes exhibit glucose intolerance in various degrees, es-
pecially during the third trimester [1]. The prevalence of
GDM is increasing globally [2]. GDM is associated with
many adverse neonatal and maternal outcomes such as
increased risk of type 2 diabetes (T2D) and hypertension
(HTN) which occurs in 2–9% of all pregnancies. The
prevalence of GDM is estimated between 1 and 14%
which varies depending on the studied population [3]. It
is estimated that the increase in the prevalence of GDM
will continue in coming years due to the ageing of
population, urban sedentary lifestyle and the increasing
number of obese women [4]. The worldwide prevalence
of GDM varies by country. In fact, approximately one of
every 20 pregnancies in Iran will be affected by compli-
cations of GDM [5, 6]. In a study conducted by Larijani
et al., the prevalence of GDM was 4.7% (3.9–5.6%) in
Tehran [7]. The prevalence of GDM in Iran has been es-
timated as 3.4% ranged from 1.3 to 18.6% [8]. Therefore,
it can be well thought out that Iranian women are a par-
ticularly high- risk population.
GDM is associated with serious complications for both
pregnant mother and her fetus [9]. There is a 2-fold in-
creased risk of cesarean section and macrosomia, a 3-fold
increased risk of neonatal hypoglycemia and hypocalce-
mia, and a 5-fold increased risk of still- birth in women
with GDM compared with non-GDM ones [7]. Hence, the
evaluation of the GDM should be considered at the first
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visit of pregnancy [10]. All acknowledged diagnostic
methods used for screening of GDM are routinely carried
out at 24–28 weeks of gestation based on monitoring of
concentration of glucose in blood [11].
Metabolomic profiling, as a systematic study of small
molecule products of biochemical pathways, is an effi-
cient method for the identification of novel biomarkers
and mechanisms related to a variety of diseases. The
findings of previous metabolomic studies have indicated
that branched chain amino acids (BCAAs), such as leu-
cine, isoleucine, valine and aromatic amino acids, like
tyrosine and phenylalanine could be used as a predictive
marker of T2D [12].
Several studies have indicated that adiponectin, apoli-
poprotein CIII, and follistatin-like-3 can be considered
as the early diagnostic biomarkers of GDM [13–15].
Recently, Bentley-Lewis et al. have maintained that the
levels of six metabolites, including anthranilic acid,
alanine, glutamate, creatinine, allantoin, and serine are
significantly different between the GDM and control
groups. In addition, the levels of BCAAs did not differ
significantly between GDM and women with normal
glucose tolerance [16].
However, the exact association between the concentra-
tion of amino acids in blood and the pathways of glucose
metabolism in pregnancy is not yet fully elucidated.
Therefore, we conducted this study to determine the
plasma free amino acid profiling in women with GDM,
diabetic pregnant and normal pregnant women to explore
the blood profiles of amino acids and its association with
GDM and diabetes mellitus during pregnancy.
Methods
Subjects
This case–control study was performed among pregnant
women referred to prenatal care clinic in Arash hospital of
Tehran, Iran, between Januarys to April 2016. Eighty three
pregnant women aged 18–40 years with gestational age
of ≥25 weeks were recruited. All participants were divided
into three groups; 1) pregnant women with normal glu-
cose tolerance test, 2) pregnant women with T2D before
pregnancy or fasting blood sugar (FBS) > 95 mg/dl or 2-h
post-GTT blood glucose <200 mg/dl in first trimester and
3) pregnant women with GDM based on ADA criteria [3].
The clinical exclusion criteria were: diabetes type 1,
chronic complication of diabetes type 2 (nephropathy, ret-
inopathy, and cardiovascular disease), gestational complica-
tion (premature delivery, premature rupture of membrane
and pre eclampsia), chronic disease requiring medication
during pregnancy, assisted reproductive technology preg-
nancies with the need to use hormones during pregnancy
and renal diseases.
This study was approved by the Ethics Committee of
the Endocrinology and Metabolism Research Institute
(EMRI) affiliated with Tehran University of Medical
Sciences. all participants signed an informed consent
form and were informed about their rights according to
the Helsinki declaration.
Clinical and laboratory measurements
The questionnaires were completed by a trained nurse
and the participants were requested to answer the ques-
tions carefully. Height and weight were measured ac-
cording to a standard protocol by a team of trained
nurses. Pre-pregnancy body mass index (BMI) was cal-
culated using self-reported weight (kg) at 3 months be-
fore conception and divided by maternal height in
meters squared (kg/m2). Brachial blood pressure was
measured by trained nurses 3 times in the right arm
after a 10-min rest period, using a manual mercury
sphygmomanometer. A fasting blood sample was taken
from all participants after 12 h fasting. Serum and
plasma samples were separated from blood within 1 to 3 h
following blood collection. Serum was separated by centri-
fugation at 500 × g for 10 min, and plasma was separated
at 350 × g for 15 min at room temperature and then
stored in −80 C until analysis. The concentration of FBS,
urea and creatinine were measured by commercial kits
(Pars Azmoon, Iran). Amino acid profiles were measured
by HPLC method (Agilent Technologies).
Statistical analysis
The Kolmogorov–Smirnov test was used to check the
normal distribution of continuous variables. The continu-
ous variables with and without normal distribution were
described as means (standard deviations (SD)) and median
(interquartile range (IQR)), respectively. Categorical vari-
able were reported as number and percentages.
The plasma levels of amino acids between groups (NG,
T2D and GDM) were compared using ANOVA for vari-
ables with a normal distribution and the Kruskal–Wallis
test for variables with a skewed distribution. The multivari-
ate multinomial logistic regression analysis applied to ex-
plore the association of each metabolite with the risk of
developing GDM or T2D after adjustment for pregnancy
age and BMI. Results of multinomial logistic regression
analysis were reported as odds ratio (OR) and 95% confi-
dence interval. Standardized scale (Z-score) of each metab-
olite were used in the multinomial logistic regression
analysis. Statistical analysis was performed using SPSS 16.
Considered-value less than 0.05 were considered as statisti-
cally significant.
Results
The basic characteristics of the participants are pre-
sented in Table 1. As data show in Table 1, pregnant
women with T2D had significantly higher BMI than
controls (P-value = 0.03). As expected, we find that
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women with T2D or GDM had higher blood concen-
tration of FBS than women with normal glucose tol-
erance (P-value <0.001). Maternal plasma amino acid
concentrations in the 3 groups of pregnant women
are presented in Table 2. Compared with normal
mothers, GDM mothers show higher plasma concentra-
tions of arginine (p value = 0.01), glycine (p value = 0.01)
and methionine (p value = 0.04), whereas the pregnant
women with T2D had higher plasma levels of aspara-
gine (p value = 0.01), tyrosine (p value <0.01), valine
(p value <0.01), phenylalanine (p value <0.01), glutamine
(p value <0.01) and isoleucine (p value <0.01).
The results of multivariate multinomial logistic regres-
sion indicated that the increase in plasma level of amino
acids, including asparagine (OR: 3.64, 95% CI: 1.22–
10.74), threonine (OR: 1.95, 95% CI: 1.05–3.60),








Age (year) 29.46 (5.45) 32.65 (5.56) 32.30 (4.89) 0.06
Weight (Kg) 72.63 (11.16) 81.34 (13.00) 82.92 (11.74) <0.001b, a
Height (m) 159.62 (3.63) 163.13 (6.70) 163.38 (7.05) 0.04b, a
BMI (Kg/m2) 28.51 (3.66) 30.43 (3.50) 31.12 (4.51) 0.03b, a
FBS (mg/dl) 78.75 (4.86) 96.44 (12.03) 146.09 (50.59) <0.001b, Ϯ
Pregnancy age (yrs) 28.48 (5.53) 29.14 (6.93) 20.29 (4.38) <0.001b, Ϯ
parity 3.04 (4.41) 2.34 (0.93) 2.04 (1.13) 0.38
aComparison GDM and NG, bcomparison T2D and NG, ϮComparison GDM and T2D
Data are presented as mean (SD)
NG pregnant women with normal glucose tolerance test, GDM women with gestational diabetes mellitus, T2D pregnant women with type 2 diabetes mellitus
Boldface indicates significance of data with p_value <0.05










ASN 35.37 (28.23–40.53) 39 (22.09–53.69) 25.48 (19.70–31.81) 0.01
SER 67.54 (52.13–95.75) 65.44 (41.37–94.41) 72.85 (54.93–87.09) 0.60
HIS 39.57 (27.57–67.69) 33.88 (23.23–56.9) 45.78 (22.13–80.71) 0.39
ARG 61.50 (38.72–84.34) 34.45 (25.47–64.13) 41 (30.11–65.39) 0.01
CIT 20.62 (15.16–29.6) 23.02 (13.80–34.09) 16.69 (13.09–22.74) 0.26
GLY 135.48 (79.77–162.88) 44.04 (20.48–146.37) 105.51 (82.73–139.19) 0.01
THR 128.8 (86.79–206.44) 100 (64.56–197.83) 88.39 (69.38–133) 0.08
TYR 39.28 (30.70–46.64) 49.24 (40.1–66.6) 35.87 (25.58–42.13) <0.01
MET 24.42 (17.56–29.01) 18.9 (14.19–25.45) 20.02 (14.59–23.07) 0.04
VAL 166.54 (129.21–210.76) 270.69 (215.06–366.65) 135.30 (110.36–175.52) <0.01
PHE 49.74 (32.91–54.61) 54.26 (45.06–67.35) 42 (28.99–48.78) <0.01
LEU 95.02 (67.14–1130.50) 104.38 (72.17–148.20) 73.52 (62.93–107.91) 0.07
ORN 21.55 (15.98–32.73) 19.51 (10.08–33.87) 19.7 (13.01–38.47) 0.50
ASP 11.01 (9.54–15.15) 10.22 (6.36–13.01) 9.16 (6.24–12.21) 0.05
GLU 98.60 (75.72–152.132) 124 (83.92–174) 71.41 (48.13–114) <0.01
GLNc 312.86 (89.18) 267.42 (86.9) 298.59 (123.41) 0.20
ALAc 288.47 (97.03) 271.77 (119.82) 290.52 (133.26) 0.80
TRPc 32.97 (13.15) 35.4 (18.89) 36.08 (19.94) 0.76
ILEc 55.38 (18.94) 84.28 (34.53) 52.01 (20.91) <.001Ϯ, b
LYSc 175.44 (58.35) 134.59 (65.11) 164.38 (85.24) 0.07
aComparison GDM and NG, bcomparison T2D and NG, ϮComparison GDM and T2D
cData presented as mean (SD)
Data presented as median (IQR)
According to Kruskal Walis
Boldface indicates significance of data with p_value <0.05
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aspartate (OR: 3.92, 95% CI: 1.19–12.91), phenylalanine
(OR: 2.66, 95% CI: 1.01–6.94), glutamine (OR: 2.53, 95%
CI: 1.02–6.26) and arginine (OR: 1.83, 95% CI: 1.02–
3.30) increased the risk of GDM (Table 3). In addition,
an increase of one SD of plasma level of amino acids
such as asparagine (OR: 2.36, 95% CI: 1.15–4.65), isoleu-
cine (OR: 4.81, 95% CI: 2.10–11.03), valine (OR:7.70,
95% CI: 2.66–22.27), phenylalanine (OR: 3.01, 95% CI:
1.21–6.26) and glutamine (OR: 2.99, 95% CI: 1.26–7.11)
increased the risk of T2D compared to normal pregnant
women (P-value <0.05 for all).
Discussion
To our knowledge, this is the first report describing the
effect of GDM and T2D on the concentration of amino
acids during the pregnancy period among Iranian
women. We conducted an exploratory metabolomic ana-
lysis on 83 pregnant women including 31 women with
GDM, 27 women with T2D and 25 women with normal
glucose tolerance. The highest plasma levels of arginine,
glycine, and methionine were observed in GDM women,
while the pregnant women with T2D had the highest
plasma level of asparagine, tyrosine, valine, phenylalanine,
glutamic acid, and isoleucine compared to other groups
which were statistically significant. In the present study,
decreased plasma levels of serine, histidine, alanine, and
tryptophan were also observed in both groups of pregnant
women with GDM or T2D. However, these differences
were non-significant.
There are limited studies to date evaluating the varia-
tions in the plasma levels of amino acids in GDM. Cetin
et al. in their study of 16 normal and 17 GDM pregnan-
cies have shown that only ornithine significantly in-
creased in GDM mothers. Also, An increase in the levels
of valine, methionine, phenylalanine, isoleucine, leucine,
ornithine, glutamate, proline, and alanine along with a
significant decrease in the level of glutamine in umbilical
vein and artery of women with GDM were reported
compared to the normal pregnant women [17]. However,
it is important to underline the deference between the 2
studies. The BMI of GDM mothers in our study was
higher than those in Cetin et al. study (30.43 ± 3.50 vs.
28.0 ± 1.6 kg/m2). The results of our study illustrated a
significant elevated plasma level of Asparagine, Threonine,
Aspartate, phenylalanine, glutamate, and arginine in GDM
women after adjustment for gestational age and BMI.
In the previous studies, the targeted metabolimoic as-
says have demonstrated the increased level of alanine,
proline, glutamine/glutamate, arginine, and asparagine/
aspartate in subjects with higher level of fasting blood sugar
[18]. Bentley-Lewi et al., by conducting a nested case–con-
trol study among pregnant women aged 18–40 year, re-
ported that of the 91 studied metabolites, one can name
anthranilic acid, alanine, glutamate, allantoin, and serine as
Table 3 Association of amino acids with GDM, T2D and normal




OR 95% CI P value OR CI P value
ASN GDM/NGa 1.57 0.77–3.22 0.21 3.64 1.22–10.74 0.01
T2D/NG 2.36 1.15–4.85 0.01 6.78 1.92–23.91 <0.01
SER GDM/NG 1.10 0.66–1.83 0.70 1.25 0.67–2.34 0.46
T2D/NG 0.79 0.42–1.46 0.45 0.73 0.32–1.63 0.44
HIS GDM/NG 0.68 0.39–1.16 0.15 0.74 0.41–1.33 0.32
T2D/NG 0.46 0.23–0.89 0.02 0.27 0.08–0.84 0.02
GLN GDM/NG 1.25 0.73–2.14 0.40 1.39 0.75–2.57 0.29
T2D/NG 0.65 0.34–1.21 0.18 0.73 0.34–1.57 0.42
CIT GDM/NG 1.10 0.6–2.03 0.74 1.40 0.60–3.23 0.43
T2D/NG 1.84 0.90–3.74 0.09 1.44 0.65–3.17 0.36
GLY GDM/NG 1.03 0.62–1.71 0.32 0.75 0.43–1.31 0.31
T2D/NG 0.48 0.25–0.94 0.03 0.41 0.16–1.05 0.06
THR GDM/NG 1.95 1.05–3.60 0.03 3.38 1.39–8.25 <0.01
T2D/NG 1.52 0.77–2.98 0.22 4.12 1.49–11.41 <0.01
ILE GDM/NG 1.24 0.59–2.57 0.56 1.19 0.54–2.62 0.69
T2D/NG 4.81 2.10–11.03 <0.01 4.99 1.63–15.20 <0.01
LEU GDM/NG 1.36 0.71–2.61 0.30 1.50 0.67–3.36 0.32
T2D/NG 2.32 1.15–4.68 0.02 1.35 0.56–3.25 0.51
ORN GDM/NG 0.79 0.46–1.34 0.37 0.86 0.47–1.55 0.62
T2D/NG 0.76 0.42–1.35 0.34 0.38 0.15–0.97 0.01
LYS GDM/NG 1.18 0.66–2.11 0.57 1.05 0.95–1.15 0.29
T2D/NG 0.58 0.29–1.14 0.12 0.83 0.76–0.93 <0.01
ASP GDM/NG 2.44 0.90–6.65 0.08 3.92 1.19–12.91 0.02
T2D/NG 2.31 0.83–6.42 0.11 3.19 0.95–1.067 0.06
TYR GDM/NG 1.09 0.54–2.21 0.79 1.08 0.51–2.26 0.83
T2D/NG 2.64 1.27–5.50 <0.01 1.74 0.76–3.96 0.19
TRP GDM/NG 0.82 0.48–1.42 0.42 0.79 0.45–1.40 0.43
T2D/NG 0.96 0.56–1.65 0.89 0.64 0.29–1.42 0.27
MET GDM/NG 2.48 0.64–9.57 0.18 4.57 0.94–21.91 0.05
T2D/NG 0.81 0.45–1.45 0.48 0.77 0.36–1.65 0.50
VAL GDM/NG 1.89 0.71–4.51 0.21 2.11 0.77–5.77 0.14
T2D/NG 7.70 2.66–22.27 <0.01 4.85 1.55–15.14 <0.01
PHE GDM/NG 2.07 0.95–4.55 0.06 2.66 1.01–6.94 0.04
T2D/NG 3.01 1.21–6.26 <0.01 3.12 1.09–8.95 0.03
GLU GDM/NG 2.19 0.93–5.14 0.07 2.53 1.02–6.26 0.04
T2D/NG 2.99 1.26–7.11 0.01 3.26 1.19–8.88 0.02
ARG GDM/NG 1.83 1.02–3.30 0.04 1.96 1.02–3.76 0.04
T2D/NG 0.84 0.44–1.59 0.59 1.00 0.46–2.18 0.90
AlA GDM/NG 1.20 0.71–2.04 0.48 1.42 0.76–2.65 0.27
T2D/NG 0.84 0.47–1.50 0.56 0.90 0.41–1.99 0.81
NG pregnant women with normal glucose tolerance test, GDM women with
gestational diabetes mellitus, T2D pregnant women with type 2 diabetes mellitus
Metabolite levels were standardized to SD unit
aadjusted for gestational age and body mass index (BMI)
Boldface indicates significance of data with p_value <0.05
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being significantly higher and creatinine as significantly
lower in GDM women compared to non-GDM ones [16].
Previous studies have confirmed that BCAAs, includ-
ing isoleucine, leucine, and valineas well as aromatic
amino acids such as phenylalanine and tyrosine were
strongly associated with insulin resistance and T2D
[12, 19–22]. However, there is a controversy about
the association between BCAAs and GDM. Although
some researchers have found elevated concentration
of branched amino acids in blood of those suffering
GDM [23], other studies have not confirmed this as-
sociation [17, 24]. In consistent with the increased of
BCAAs in type 2 diabetic patients, the results of the
present study showed higher plasma concentration of
valine, isoleucine in T2D pregnant women compared
to GDM and non-GDM ones. It was shown that an
increase in the hepatic gluconeogenes entails the in-
creased level of BCCAs in blood. Patients with insulin
resistance have reduced activities of BCAAs catabolic
enzymes in liver and adipose tissues, which are asso-
ciated with the higher blood concentration of BCAAs
[19, 25]. Some of the previous studies have demon-
strated that aromatic amino acid are associated with
insulin resistance [26] especially in pregnant women
with T2D [12] and GDM [27] while, other investiga-
tions didn’t find any statistically significant correlation
between the plasma level of these amino acids and
GDM [17, 23, 24]. In present study, we found signifi-
cantly elevated levels of tyrosine and phenylalanine in
T2D, but not among GDM mothers.
Another study found that of the 21 amino acids, only
methionine, glycine, alanine, citrulline, and ornithine
levels were significantly higher in normal pregnant
women compared to those with GDM [28]. Similar to
this study, only the plasma level of alanine was higher in
normal pregnant women compared to GDM and T2D
groups which was statistically non-significant. The
mechanisms of these observations were investigated in
the same study. They suggested that the elevation of ke-
tone bodies in the GDM group may inhibit the proteino-
lysis and reduces the oxidation of BCAAs and other
ketogenic amino acids in skeletal muscles, simultan-
eously. Therefore, the ketogenic amino acids (lysine) and
the branched-chain amino acids, such as isoleucine and
leucine are released at low rates from skeletal muscle
and are mostly catabolized in the liver rather than in
peripheral tissues in GDM mothers [28].
Analyses of conventional metabolites of 67 Northern
European mothers with high FBS (>90th percentile) and
50 mothers with low FBS (<10th percentile) indicated
that high FBS mothers had higher blood level of alanine,
proline, and BCAAs that together with higher triglycer-
ides, 3-hydroxybutyrate, had consistency with insulin re-
sistance in this groups [29]. In this study, the metabolic
profiling were determined using targeted and untargeted
metabolomic assays. However, in contrast to this study,
we observed that the plasma level of alanine was higher
in normal pregnant women compared to those with
GDM or T2D. The elevated levels of valine, and isoleu-
cine in pregnant women with T2D compared to other
groups confirm the association of BCAAs and hypergly-
cemia in this study and the previous ones [30–32].
The controversy in these results could be explained by
the differences in the genetic background and environmen-
tal influences on GDM group. Previous studies have been
implemented through using different methods to assess
metabolomic profiling, including targeted and untargeted
approaches to metabolomic using ultra-performance liquid
chromatography tandem mass-spectrometry (UPLC-MS)
or high-resolution gas chromatography time-of-flight mass
spectrometry or liquid chromatography tandem mass
spectrometry (LC-MS/MS) and etc. for targeted and
untargeted. In this study, ultra-performance liquid
chromatography was used for the screening of meta-
boloms in plasma samples. In addition, differences in
the efficient control of glucose and the trimesters of
pregnancy may be other reasons.
The limitation of the present study is the small sample
size. Therefore, the cohort studies with larger sample
sizes are needed to investigate the role of metaboloms
including free amino acids in the prediction of GDM.
Conclusion
In conclusion, this investigation showed that amino
acids levels are associated with higher risk of T2D and
GDM. However, further prospective studies should be
conducted to clarify the role of different metabolites in-
volved in the mechanism of GDM. By considering the
increasing prevalence of diabetes in the world, effective
methods such as metabolomic investigations are needed
to make the prediction and early diagnosis of GDM pos-
sible in pregnant women.
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